Richter Gedeon stock: Results due November 10 after first-half revenue rose 3.00 percent

Published on 10/21/2026 at 16:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Clean EBIT rose 21.00 percent in the first half of 2026, while pharma guidance reached double digits. Richter Gedeon stock costs EUR 34.76 on October 21, 2026.

Operating figures and dates

Gedeon Richter is scheduled to report results on November 10, 2026.
Revenue reached HUF 151.80 billion in the first half of 2026, up 3.00 percent year over year.
Richter Gedeon stock costs EUR 34.76 at Lang & Schwarz on October 21, 2026 at 4:08 p.m. CEST.

Richter Gedeon, HU0000123096, Illustration mit AI erstellt.

Richter Gedeon (ISIN HU0000123096) is scheduled to report its next results on November 10, 2026, while first-half revenue had reached HUF 151.80 billion, up 3.00 percent year over year. The stock was trading at EUR 34.76 at Lang & Schwarz on October 21, 2026 at 4:08 p.m. CEST.

First-half results set the tone

The latest reported period showed stronger operating momentum beneath the revenue increase. According to the Yahoo Finance transcript dated August 7, 2026, constant-currency Clean EBIT rose 21.00 percent in the first half of 2026. Management also upgraded 2026 pharmaceutical Clean EBIT guidance to double-digit growth on a constant-currency basis.

What comes before the results?

The next dated event is the November 10 reporting appointment. Yahoo Finance lists November 10, 2026 as Gedeon Richter's earnings announcement date. The appointment gives investors a clear point for testing whether the first-half pattern has continued into the second half.

Pharmaceutical margins matter

The operating figures point to a margin-led reading of the next report. Clean EBIT growth of 21.00 percent exceeded the 3.00 percent increase in first-half revenue, while the company said constant-currency pharmaceutical Clean EBIT should grow at a double-digit rate in 2026. The transcript also recorded HUF 4.5 billion of restructuring costs in the first half, a figure that helps separate operating progress from one-time charges.

Richter Gedeon price and dates

Richter Gedeon develops and sells pharmaceutical products across women's healthcare, central nervous system, cardiovascular and other therapeutic areas. Its reported first-half revenue of HUF 151.80 billion and 21.00 percent Clean EBIT growth provide the principal operating markers ahead of the November 10 date.

Richter Gedeon was trading at EUR 34.76 at Lang & Schwarz on October 21, 2026 at 4:08 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Richter Gedeon stock.